Assessing Cosopt Switch Patients

Pharmaceutical Research Network60 enrolled

Overview

To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Ocular Hypertension Open-Angle Glaucoma Exfoliation Syndrome Glaucoma, Pigmentary

Interventions

timolol maleateDRUG

dorzolamide/timolol maleate fixed combinationDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension * the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM * visual acuity should be 20/200 or better in each eye Exclusion Criteria: * contraindications to study drugs * anticipated change in systemic hypotensive therapy during the trial * use of any corticosteroids by any route in the three months immediately prior to Visit 2

Locations (5)

Little Rock Eye Clinic

Little Rock, Arkansas, United States

Omni Eye Services

Atlanta, Georgia, United States

Midwest Eye Center

Bourbonnais, Illinois, United States

Mark J. Weiss, MD

Tulsa, Oklahoma, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.